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Abstract
Purpose: Currently, a variety of red and green beetle luciferase variants are available for
bioluminescence imaging (BLI). In addition, new luciferin analogues providing longer wavelength
luminescence have been developed that show promise for improved deep tissue imaging.
However, a detailed assessment of these analogues (e.g., Akalumine-HCl, CycLuc1, and amino
naphthyl luciferin (NH2-NpLH2)) combined with state of the art luciferases has not been
performed. The aim of this study was to evaluate for the first time the in vivo brightness and
spectral characteristics of firefly (Luc2), click beetle green (CBG99), click beetle red 2 (CBR2),
and Akaluc luciferases when paired with different D-luciferin (D-LH2) analogues in vivo.
Procedures: Transduced human embryonic kidney (HEK 293T) cells expressing individual
luciferases were analyzed both in vitro and in mice (via subcutaneous injection). Following
introduction of the luciferins to cells or animals, the resulting bioluminescence signal and photon
emission spectrum were acquired using a sensitive charge-coupled device (CCD) camera
equipped with a series of band pass filters and spectral unmixing software.
Results: Our in vivo analysis resulted in four primary findings: (1) the best substrate for Luc2,
CBG99, and CBR2 in terms of signal strength was D-luciferin; (2) the spectra for Luc2 and CBR2
were shifted to a longer wavelength when Akalumine-HCl was the substrate; (3) CBR2 gave the
brightest signal with the near-infrared substrate, NH2-NpLH2; and (4) Akaluc was brighter when
paired with either CycLuc1 or Akalumine-HCl when paired with D-LH2.
* The Author(s), 2020
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Conclusion: We believe that the experimental results described here should provide
valuable guidance to end users for choosing the correct luciferin/luciferase pairs for a
variety of BLI applications.
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Introduction
Bioluminescence imaging (BLI) is a well-known, non-
invasive technique employed during preclinical studies to
track cells and monitor biological processes in living animals
[1–3]. BLI is performed by capturing the light generated by
a luciferase upon exogenous substrate (e.g., D-luciferin (D-
LH2)) addition to report real-time, cellular, and molecular
events [4].
Over the last decade, the bioluminescence toolbox has
greatly expanded [1, 5, 6]. Novel luciferin analogues have
been introduced that enhance light emission in vivo and
increase detection sensitivity in deeper tissues [7]. Cycluc1
has been shown to enhance emission of codon optimized
firefly luciferase (Luc2), especially in the brain. Further-
more, this system provides slightly red-shifted emission
resulting in deeper light penetration and less scattering of the
bioluminescence signal [8, 9]. Likewise, Akalumine-HCl has
a spectral peak in the near infrared (NIR) (677 nm) and
enhanced emission with Luc2 when administered at low
concentration [10]. Akalumine-HCl paired with the recently
engineered Akaluc luciferase is even brighter, although the
spectral peak is blue-shifted to 650 nm [11]. Amino naphthyl
luciferin (NH2-NpLH2) represents another new substrate
with potential for deeper tissue BLI [12]. This substrate was
shown to emit in the NIR with a peak of 740 nm when
reacting with an engineered version of click-beetle luciferase
(CBR2). CBR2 can also utilize D-LH2 and this combination
was shown to improve imaging in black fur mice compared
with Luc2/ D-LH2.
Research into the development of improved BLI reagents
has generally focused on bioluminescence systems com-
prised of compatible luciferase/luciferin pairings [13–18].
Most comparative studies have been performed using D-
LH2. For example, Miloud et al. compared firefly (Luc2)
and click beetle luciferases in vivo with D-LH2 as substrate
and concluded that click beetle green (CBG99) has
sensitivity and total photon yield comparable with click
beetle red [15]. In other studies, Luc2 was shown to have
improved performance compared with a red-shifted firefly
mutant (PpyRE9) and CBG99 for brain imaging [16, 17],
but D-LH2 was the only substrate examined. A direct
comparison (either in vitro or in vivo) of emission spectra
and relative brightness of bioluminescence systems com-
prised of different luciferase enzymes in combination with
novel luciferins has, to date, not been reported.
Here, we provide a detailed in vitro and in vivo analysis
of brightness and emission spectra for four luciferases when
combined with four different substrates using a CCD camera
equipped with a series of band pass filters and spectral
unmixing software. We anticipate that the results of this
comparative analysis will help enable researchers to choose
the best enzyme/substrate pairs for different BLI applica-
tions. In addition, our findings revealed that depending on
the luciferase/luciferin pair, a wide range of spectral
emission peaks (i.e., multicolored luciferases) is available
that could broaden the BLI toolbox in the future for
multiplex analysis both in vitro and in vivo.
Materials and Methods
Animals
Animal experiments were approved by the Bioethics
Committee of Erasmus MC, Rotterdam, The Netherlands,
and performed in accordance with national guidelines and
regulations established by the Dutch Experiments on Animal
Act (WoD) and by the European Directive on the Protection
of Animals used for scientific purpose (2010/63/EU).
BALB/C nude (females) were obtained from Charles River
Laboratory (The Netherlands). All mice aged 6–8 weeks
were provided access to food and water ad libitum and were
hosted in the animal facility at the Erasmus MC, Rotterdam,
The Netherlands.
Cell Line
Human embryonic kidney cells (HEK 293T) were cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma,
St. Louis, MO, USA) supplemented with 10 % of FBS and
1 % Penicillin-Streptomycin. The culture was incubated at
37 °C with 5 % CO2.
Lentivirus Production
Virus production and cell transduction were performed
under appropriate biosafety level conditions (ML-II) in
accordance with the National Biosafety Guidelines and
Regulations for Research on Genetically Modified Organ-
isms. Procedures and protocols were reviewed and approved
by the EMC Biosafety Committee (GMO permit 99-163).
The lentiviral plasmids pCDH-EF1-CBG99-T2A-copGFP,
pCDH-EF1-Luc2-T2A-copGFP, and pCDH-EF1-CBR2-
T2A-copGFP were previously described [12, 15]. The
plasmid pCDH-EF1-Akaluc-T2A-copGFP was produced by
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inserting the sequence of Akaluc (amplified with specific
primers from pcDNA3 Venus-Akaluc plasmid from RIKEN
BRC repository) without stop codon using BamHI and NotI
sites in pCDH-EF1-MCS-T2A-copGFP vector. Lentiviruses
were produced by transfection of HEK 293T packaging cells
with three packaging plasmids (pCMV-VSVG, pMDLg-
RRE, pRSV-REV; Addgene, Cambridge, MA, USA) and
the lentiviral vector plasmids as previously described in
details [16].The supernatant containing lentiviral particles
were collected after 48 and 72 h. Subsequent quantification
of the virus was performed using a standard antigen-capture
HIV p24 ELISA (ZeptoMetrix Corporation, NY, USA).
Cell Transduction and Transfection
Cell transduction was performed by culturing HEK 293T
cells in DMEM supplemented with 10 % of FBS and 1 % of
Penicillin-Streptomycin at the density of 200,000 cells in a
T25-flask with 5 ml of medium. Expression in the lentiviral
plasmid is driven by housekeeping elongation factor 1α
(EF1) promoter. Cells were transduced with MOI 1 of either
pCDH-EF1-Luc2-T2A-copGFP, pCDH-EF1-CBG99-T2A-
copGFP, pCDH-EF1-CBR2-T2A-copGFP, or pCDH-EF1-
Akaluc-T2A-copGFP lentivirus plus with polybrine
(hexametride bromide, Sigma-Aldrich) at the final concen-
tration of 8 μg/ml. Transgene expression was confirmed by
the presence of the super bright green fluorescent protein
copGFP from the copepod Potentilla plumata (excitation/
emission maximum = 482/502 nm).
Flow Cytometry to Sort Stable Cell Lines
Positive stable clones were sorted for comparable levels of
copGFP expression by cell sorting (BD-FACS ARIA III, BD
Biosciences). Forward and side scatters were also drawn to
eliminate cellular debris from the analysis and to select
highly positive cells for GFP.
In Vitro BLI
Transduced cells were plated at a density of 2 × 104 cells per
well in a black 96-well plate (Greiner Cell Star®) and
imaged in 100 μl of D-PBS. Bioluminescence signal from
wells was measured with IVIS® spectrum system
(PerkinElmer, Boston, MA, USA) every 5 min after
substrate addition (final concentration of each substrate
was 0.1 mM). All in vitro measurements were acquired
after 1 min at 37 °C using a 30-s acquisition time with an
open filter or using a series of band pass filters ranging from
520 to 800 nm. Data were analyzed by the Living Image
software version 4.3 (PerkinElmer). Data in every well were
normalized for fluorescence emission detected using a
GloMax®-Multi plate reader.
In Vivo BLI
Each stable expressing cell line was injected subcutaneously
1 × 105 cells/50 μl. The number of animals was chosen
according to power analysis (p value at least G 0.05 and
power 95 %) considering that we expected from the data
generated in vitro that the brightest BL system would differ
by 1–2 orders of magnitude in vivo. Mice (N = 3 per group)
received two different cell lines, one in each flank. Animals
were then imaged after intraperitoneal injection of D-LH2
substrate (150 mg/kg), NH2-NpLH2 substrate (220 mg/kg),
CycLuc1 (7.6 mg/kg), and Akalumine-HCl substrate
(50 mg/kg). These doses were chosen based on maximum
solubility (for CycLuc1 and Akalumine-HCl), tolerability in
mice, and maximum attainable signal based on previous
findings. Mice were randomly assigned and anesthetized by
isoflurane inhalation prior to performing BLI imaging. The
person performing the subcutaneous injections was blind as
to the cells being injected. Images were acquired with the
IVIS® spectrum small animal imager system (PerkinElmer).
Light was measured using open filter and a series of 20 nm
wavelength band filters from 520 to 800 nm with acquisition
time of 30 s during a time of about 30 min after substrate
injection (kinetic analysis). Emission signals were measured
with the Living Image software® version 4.3 (Perkin
Elmer).
Statistical Analysis
All statistical analyses were performed using the GraphPad
Prism 6 software and one-way ANOVA followed by
Tukey’s post-test. p values G 0.05 were considered statisti-
cally significant.
Results
In Vitro Evaluation of Emission Properties for
Different Combinations of Luciferase Variant and
Luciferin Analogue
The aim of this study was to evaluate in vitro and in vivo
light emission and spectral differences between four lucifer-
ases (Luc2, CBG99, CBR2, and Akaluc) when combined
with D-LH2 or three luciferin analogues (NH2-NpLH2,
Akalumine-HCl, or CycLuc1) for bioluminescence imaging
(BLI). To compare the different emissions, HEK 293T cells
stably expressing each of the four luciferases were treated
with substrates (0.1 mM) and imaged at 37 °C. Equimolar
expression of each luciferase was achieved by selecting cells
for GFP emission.
We found that the luciferase/luciferin pairs yielding the
highest photon emission (p value G 0.001) were Luc2/D-LH2
and Akaluc/CycLuc1 when the substrate was added at a
concentration of 0.1 mM. The combinations of
Luc2/CycLuc1, Akaluc/Akalumine-HCl, CBG99/D-LH2,
Fig. 1. (a) Bioluminescence profiles for Luc2, CBR2, CBG99, and Akaluc luciferases combined with four different luciferin
analogues in live cells. (b-f) Photon flux (ph/s) in HEK 293T cells expressing individual luciferases upon addition of substrates
(0.1 mM) was quantified using an exposure time of 30 s. Statistical analysis (N = 3) was performed using one-way ANOVA
followed by Tukey’s T test (*p G 0.01 for Luc2/D-LH2 compared with all combinations with the exception of Akaluc/Cycluc1
which was not significantly different).
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and CBR2/D-LH2 produced ~ 2-fold fewer photons (Fig.
1a), while cells expressing CBG99 were much less efficient
(~ 100-fold dimmer with NH2-NpLH2/Akalumine-HCl; 10-
fold dimmer with CycLuc1) (Fig. 1a). CBR2-expressing
cells were more promiscuous compared with CBG99 cells.
However, they generated 10-fold less luminescence (com-
pared with Luc2/D-LH2) with Akalumine-HCl and NH2-
NpLH2. The CBR2-expressing cells gave a signal
Fig. 2. In vivo (BALB/C) emission spectra for different combinations of luciferase (Luc2, CBG99, CBR2, or Akaluc; expressed
in HEK393T cells implanted subcutaneously in the flanks) and luciferin or luciferin analogue. (a) D-LH2 (150 mg/kg), (b) NH2-
NpLH2 (220 mg/kg), (c) CycLuc1 (7.6 mg/kg), and (d) Akalumine-HCl (50 mg/kg); substrates were injected intraperitoneally).
Spectral data was acquired 15–20 min after injection.
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comparable with Luc2/D-LH2 with CycLuc1. Finally,
Akaluc produced similar luminescence intensity when either
Akalumine-HCl or CycLuc1 was used as substrate (Fig. 1a).
Akaluc also showed nearly 100-fold lower signal with D-
LH2 or NH2-NpLH2 compared with Akalumine-HCl and
CycLuc1.
In Vivo Emission Spectrum of Luciferases
Detected Using a Series of 20 nm Band Pass
Filters
The day of injection, HEK 293T cells (expressing the various
luciferases) were prepared at a concentration of 2 × 106 cells/ml in
PBS and fluorescence emission measured at IVIS, confirming the
comparable average expression of GFP (Supplementary Fig. 1).
Following subcutaneous injection of 1 × 105 HEK 293T cells
(expressing the various luciferases) into both flanks of mice,
images were acquired after injection of D-LH2 (150mg/kg), NH2-
NpLH2 (220 mg/kg), Akalumine-HCl (50 mg/kg), or CycLuc1
(7.6 mg/kg). We used the optimal concentration for each given
substrate based on previous literature [8, 10, 12, 19]. For D-LH2,
this was 150 mg/kg [19]. Because of poor aqueous solubility,
CycLuc1 and Akalumine-HCl were injected at 7.6 mg/kg (5 mM
in saline) and 50 mg/kg (33 mM in saline), respectively [8, 10].
We previously demonstrated that the solubility of NH2-NpLH2
allows injection of a maximal dose of 220 mg/kg (60 mM in
saline) and that it produces significantly higher photon fluxes than
a dose of 150 mg/kg [12]. Multiple acquisitions using a series of
20 nm band pass filters were performed with an exposure time of
30 s. The BLI measurements were performed at the time of peak
of emission after injection of the luciferins into sedated animals.
In terms of emission spectra, Luc2/D-LH2, CBG99/D-
LH2, CBR2/D-LH2, and Akaluc/D-LH2 produced peaks at
610 nm, 540 nm, 620 nm, and 640 nm, respectively (Fig.
2a). NH2-NpLH2 caused a red shift of the peak of emission
with all the luciferases (Luc2, 700 nm; Akaluc, 720 nm;
CBR, 730 nm; and CBG99, 620 nm) (Fig. 2b). In contrast,
when CycLuc1 was used as a substrate, the emission peak
for each luciferase was in the range of 620 nm (Luc2 and
Akaluc were green shifted towards 600 nm and CBG99 and
CBR2 were red-shifted towards 640 nm) (Fig. 2c). Akaluc/
Akalumine-HCl, also referred to as the AkaBLI system [11],
produced a peak of emission at 660 nm while the other
luciferases peaked in the NIR (~ 680 nm) when paired with
Akalumine-HCl (Fig. 2d).
In Vivo Comparison of Brightness of Luciferase/
Luciferin Pairing
Next, we compared the total emission of each luciferase
in vivo with D-LH2 or the luciferin analogues. Figure 3
shows the representative bioluminescent images of nude
mice where CBG99, Luc2, CBR2, and Aka-Luc-expressing
cells were implanted, and each of the different substrates
was injected intraperitoneally. The data in Fig. 4 represents
signals at peak of emission which differs slightly between
Fig. 3. Superficial bioluminescence imaging of BALB/C
mice in which 1 × 105 HEK293T cells transduced with Luc2
and Akaluc or CBR2 and CBG99 were implanted subcuta-
neously into the left and right flanks of mice, respectively,
and treated (intraperitoneally) with (a) D-LH2 (150 mg/kg), (b)
NH2-NpLH2 (220 mg/kg), (c) CycLuc1 (7.6 mg/Kg), and (d)
Akalumine-HCl (50 mg/kg). Imaging data was collected using
open filters and with an exposure time of 30 s. Average
luminescence is reported as photons/s/cm2/sr.
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BLI systems (Supplementary Fig. 2). Luc2, CBG99, and
CBR2 paired with D-LH2 produced the highest signals
which were 20-fold higher compared with Akaluc/D-LH2 (p
value G 0.001) (Fig. 4a). When NH2-NpLH2 was used as a
substrate, Luc2 and CBR2 produced approximately 10-fold
higher signal output (p value, 0.001) compared with both
CBG99 and Akaluc (Fig. 4b). When CycLuc1 was used as a
substrate, the strongest signal was detected for
Luc2/Cycluc1. Akaluc, CBR2, and CBG99 paired with
Cycluc1 produced ~ 5, 16, and 70-fold lower signal output,
respectively (Fig. 4c). When Akalumine-HCl was used as a
substrate, Luc2 and Akaluc produced ~ 2-fold higher signal
compared with CBR2, and there was no detectable signal for
CBG99 (Fig. 4d).
The luciferase/luciferin pairs that gave the highest photon
yields in vivo were Luc2/D-LH2, Luc2/CycLuc1, CBG99/D-
LH2, and CBR2/D-LH2 (1–2 × 107 ph/s). The following
luciferin/luciferase pairs produced approximately 10-fold
fewer photons: Akaluc/Cycluc1, Akaluc/Akalumine-HCl,
Luc2/Akalumine-HCl, Luc2/NH2-NpLH2, and CBR2/NH2-
NpLH2. Finally, the following pairs produced nearly 100-
fold fewer photons: CBR2/CycLuc1, CBR2/Akalumine-
HCl, CBG99/Cycluc1, CBG99/NH2-NpLH2, and Akaluc/
NH2-NpLH2 (Fig. 4e, Table 1).
Discussion
A variety of new luciferase enzymes and novel substrate
analogues emerging in recent years have resulted in better tools
for in vivo BLI. One example is CBR2/NH2-NpLH2, which was
engineered specifically for enhanced NIR emission to improve
imaging resolution in deeper tissues [12]. Another example is
Akaluc/Akalumine-HCl [11], an engineered pair offering im-
proved in vivo sensitivity. Another relatively new substrate,
Cycluc1, has shown in vivo utility (including more efficient
crossing of the blood brain barrier compared with D-LH2) when
used in combination with the already well-established Luc2 [8].
With the emergence of these and other new bioluminescence
systems, we felt it would be of interest and potential benefit for the
in vivo BLI community, particularly for those interested in dual
color readouts, to analyze different pairings of luciferase/substrate
using a common set of test parameters. Here, we report on the
photon yields and spectral characterization of Luc2, CBG99,
CBR2, and Akaluc luciferases combined with four different
substrates (D-LH2, NH2-NpLH2, Cycluc1, and Akalumine-HCl)
both in vitro and in vivo. Our goal was to use these parameters to
compare the various luciferase/substrate combinations in a
standard subcutaneous in vivo BLI model, with the intention to
provide guidance for the in vivo BLI community when choosing
appropriate systems for specific applications involving dual color
detection. Note the longer emission wavelengths for CBR2/NH2-
NpLH2 and Akaluc/Akalumine-HCl provide a sensitivity advan-
tage in deeper tissue [11, 12] that will not be fully realized in a
subcutaneous model. However, we postulated that the peak
emissions in the NIR for these systems would provide excellent
spectral separation from shorter wavelength signals nonetheless.
We have demonstrated in vitro that at a relatively low, but
biologically relevant (in vivo) substrate concentration (0.1 mM),
three of the four luciferases givemaximum signal when combined
with D-LH2. The exception was Akaluc, which produced more
photons when using either Cycluc1 or Akalumine-HCl as
substrate. We observed the same trend in a low-depth, superficial
in vivo tissuemodel. Thoughwe did not examine deeper tissues in
this study, we predict based on our results that the red-shifted NIR
systems (CBR2/NH2-NpLH2, Akaluc/Akalumine-HCl, and
Luc2/Akalumine-HCl) would perform best.
To evaluate spectral properties in vivo as a way to determine
the potential for multiplexing, we used the same superficial,
subcutaneous model where different luciferase expressing cell
lineswere injected into the backs ofmice. Thisminimally invasive
Fig. 4. Quantification of photon flux (ph/s) measured in vivo for all combinations of luciferase and substrate (D-LH2 (a),
Akalumine-HCl (b), CycLuc1 (c), and NH2-NpLH2 (d). Combined data is also presented in logarithmic scale (e). Statistical
analysis of data was performed using one-way ANOVA followed by Tukey’s post-test (**p G 0.0019; ***p G 0.001; ****p G 0.0001).
Zambito G. et al.: Identification of optimal luciferase/luciferin pairings for in vivo bioluminescence imaging 1529
model allowed us to determine the light emission characteristics
for different BLI systems using a small cohort of animals. Based
on the analysis, we are able to recommend new combinations of
luciferases with distinct colors having potential for multiplexing
with a single substrate in superficial tissue e.g., CBG99/D-LH2
(540 nm) and CBR2/D-LH2 (620 nm) (examples of spectral
unmixing showed in Supplementary Fig. 3); CBG99/D-LH2
(540 nm) and Luc2/D-LH2 (610 nm); and Luc2/Akalumine
(680 nm) and Akaluc/Akalumine (650 nm). Such an approach
could be useful for analyzing multiple parameters or biological
processes in animals using either engrafted cells or transgenes
expressed in particular tissues or organs, and as part of a single
imaging session requiring fewer animals.
Successful multiplexing of luminescence systems with differ-
ent emission spectra relies on the acquisition of images using
multiple filters followed by accurate, algorithm-based spectral
unmixing to resolve the contributions from each luciferase to total
light output. This can be a challenge with shorter wavelength
systems (e.g., CBG99/D-LH2), as they tend to shift their apparent
emission peak to significantly longer wavelengths when imaged in
deeper tissues or even in superficial tissue when using mice with
dark fur [20–22]. For these more challenging imaging targets, it is
therefore desirable to use bioluminescence pairs that emit in the
NIR (9 650 nm), as emission peaks are essentially constant in this
range of the spectrum [22, 23]. In this regard, we found that click
beetle luciferases have high photon emission with NH2-NpLH2
Table 1 In vivo emission intensity relative to Luc2/D-LH2
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[12] and that there is a broad spectral separation between CBG99
(620 nm) and CBR2 (720 nm) (spectral unmixing is shown in
Supplementary Fig. 2). However, before giving serious consider-
ation to this pair with NH2-NpLH2 as a multiplexing opportunity
for deep tissue imaging in mice, it will likely be necessary to
improve the photon yield for CBG99/NH2-NpLH2.
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